These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 24613178)

  • 21. [Review of the development in European Legislation on the harmonisation of the laws for medicinal products].
    Lehmann B
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul; 51(7):713-21. PubMed ID: 18584107
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The European Regulation on medicines for paediatric use.
    Dunne J
    Paediatr Respir Rev; 2007 Jun; 8(2):177-83. PubMed ID: 17574163
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The regulatory framework for complementary and alternative medicines in Europe].
    Knöss W; Stolte F; Reh K
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul; 51(7):771-8. PubMed ID: 18584103
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Paediatric investigation plans for pain: painfully slow!
    Davies EH; Ollivier CM; Saint Raymond A
    Eur J Clin Pharmacol; 2010 Nov; 66(11):1091-7. PubMed ID: 20821198
    [TBL] [Abstract][Full Text] [Related]  

  • 25. "Bonne Année", "Gutes Neues Jahr"? Will 2007 be a "Happy New Year" for children's medicines in Europe?
    Stephenson T
    Arch Dis Child; 2007 Aug; 92(8):661-3. PubMed ID: 17642477
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The consequences of 'Brexit' for drug discovery and development, and the regulatory implications.
    Golding BT; Waring MJ
    Expert Opin Drug Discov; 2018 Jul; 13(7):583-585. PubMed ID: 29634365
    [No Abstract]   [Full Text] [Related]  

  • 27. Proposals for model-based paediatric medicinal development within the current European Union regulatory framework.
    Manolis E; Pons G
    Br J Clin Pharmacol; 2009 Oct; 68(4):493-501. PubMed ID: 19843052
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Delays in completion and results reporting of clinical trials under the Paediatric Regulation in the European Union: A cohort study.
    Hwang TJ; Tomasi PA; Bourgeois FT
    PLoS Med; 2018 Mar; 15(3):e1002520. PubMed ID: 29494592
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The EU paediatric regulation: effects on paediatric psychopharmacology in Europe.
    Stoyanova-Beninska VV; Wohlfarth T; Isaac M; Kalverdijk LJ; van den Berg H; Gispen-de Wied C
    Eur Neuropsychopharmacol; 2011 Aug; 21(8):565-70. PubMed ID: 20621456
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The EU's new paediatric medicines legislation: serving children's needs?
    Permanand G; Mossialos E; McKee M
    Arch Dis Child; 2007 Sep; 92(9):808-11. PubMed ID: 17715445
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Drug evaluation in children 10years after the European pediatric regulation current challenges and perspectives.
    Élie V; Leroux S; Kaguelidou F; Jacqz-Aigrain E
    Therapie; 2018 Apr; 73(2):113-117. PubMed ID: 29580612
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pediatric formulation issues identified in Paediatric Investigation Plans.
    Quijano Ruiz B; Desfontaine E; Arenas-López S; Wang S
    Expert Rev Clin Pharmacol; 2014 Jan; 7(1):25-30. PubMed ID: 24308789
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [New EU law--an improvement for Norwegian children?].
    Kalikstad B
    Tidsskr Nor Laegeforen; 2009 Sep; 129(17):1770-2. PubMed ID: 19756062
    [No Abstract]   [Full Text] [Related]  

  • 34. [Regulatory aspects of biosimilars. Myths and facts].
    Schneider CK; Weise M
    Z Rheumatol; 2015 Oct; 74(8):695-700. PubMed ID: 26385104
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Medicines for children licensed by the European Agency for the Evaluation of Medicinal Products.
    Ceci A; Felisi M; Catapano M; Baiardi P; Cipollina L; Ravera S; Bagnulo S; Reggio S; Rondini G
    Eur J Clin Pharmacol; 2002 Nov; 58(8):495-500. PubMed ID: 12451425
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Orphan Drug Regulation: A missed opportunity for children and adolescents with cancer.
    Vassal G; Kearns P; Blanc P; Scobie N; Heenen D; Pearson A
    Eur J Cancer; 2017 Oct; 84():149-158. PubMed ID: 28818704
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Better medicines for children: European measures].
    van den Berg H; Taminiau JA
    Ned Tijdschr Geneeskd; 2008 Jul; 152(27):1537-40. PubMed ID: 18681365
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Paediatric Medicines: Regulatory and Scientific Issues.
    Daousani C; Karalis VD
    Drug Res (Stuttg); 2017 Jul; 67(7):377-384. PubMed ID: 28521373
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drug development: EU paediatric legislation, the European Medicines Agency and its Paediatric Committee--adolescents' melanoma as a paradigm.
    Rose K; Senn S
    Pharm Stat; 2014; 13(4):211-3. PubMed ID: 24903307
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Extrapolation in the development of paediatric medicines: examples from approvals for biological treatments for paediatric chronic immune-mediated inflammatory diseases.
    Stefanska AM; Distlerová D; Musaus J; Olski TM; Dunder K; Salmonson T; Mentzer D; Müller-Berghaus J; Hemmings R; Veselý R
    Arch Dis Child; 2017 Oct; 102(10):952-957. PubMed ID: 28554892
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.